Anthropic's Long-Term Benefit Trust has appointed Vas Narasimhan, CEO of Novartis, to its Board of Directors. Narasimhan's extensive experience in developing and approving new medicines in a highly regulated industry is expected to aid Anthropic in safely scaling its AI technologies. His appointment signifies the Trust's commitment to balancing Anthropic's financial goals with its public benefit mission. AI
Summary written by gemini-2.5-flash-lite from 1 source. How we write summaries →
IMPACT Strengthens Anthropic's governance with expertise in responsible scaling of complex technologies.
RANK_REASON Appointment of a CEO from a major company (Novartis) to the board of a leading AI lab (Anthropic).
